TY - JOUR
T1 - Towards Co-Creative Generative Adversarial Networks for Fashion Designers
AU - Grabe, Imke
AU - Zhu, Jichen
PY - 2023
Y1 - 2023
N2 - Originating from the premise that Generative Adversarial Networks (GANs) enrich creative processes rather than diluting them, we describe an ongoing PhD project that proposes to study GANs in a co-creative context. By asking How can GANs be applied in co-creation, and in doing so, how can they contribute to fashion design processes? the project sets out to investigate co-creative GAN applications and further develop them for the specific application area of fashion design. We do so by drawing on the field of mixed-initiative co-creation. Combined with the technical insight into GANs' functioning, we aim to understand how their algorithmic properties translate into interactive interfaces for co-creation and propose new interactions.
AB - Originating from the premise that Generative Adversarial Networks (GANs) enrich creative processes rather than diluting them, we describe an ongoing PhD project that proposes to study GANs in a co-creative context. By asking How can GANs be applied in co-creation, and in doing so, how can they contribute to fashion design processes? the project sets out to investigate co-creative GAN applications and further develop them for the specific application area of fashion design. We do so by drawing on the field of mixed-initiative co-creation. Combined with the technical insight into GANs' functioning, we aim to understand how their algorithmic properties translate into interactive interfaces for co-creation and propose new interactions.
KW - Generative Adversarial Networks
KW - Co-creative processes
KW - Fashion design
KW - Mixed-initiative co-creation
KW - Interactive interfaces
KW - Generative Adversarial Networks
KW - Co-creative processes
KW - Fashion design
KW - Mixed-initiative co-creation
KW - Interactive interfaces
U2 - 10.48550/arXiv.2304.09477
DO - 10.48550/arXiv.2304.09477
M3 - Tidsskriftartikel
SN - 2331-8422
JO - arXiv
JF - arXiv
ER -